John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

CGX1321-101

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

CO40939

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Nektar

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M14-064

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M16-438

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease.

Authors
Roe, MT; Strickler, J
MLA Citation
Roe, Matthew T., and John Strickler. “Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease..” Circulation, vol. 140, no. 18, Oct. 2019, pp. 1460–62. Pubmed, doi:10.1161/CIRCULATIONAHA.119.042875.
URI
https://scholars.duke.edu/individual/pub1417914
PMID
31657956
Source
pubmed
Published In
Circulation
Volume
140
Published Date
Start Page
1460
End Page
1462
DOI
10.1161/CIRCULATIONAHA.119.042875

ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.

<jats:p> TPS720 </jats:p><jats:p> Background: Dual variable domain immunoglobulin ABT-165 targets human vascular endothelial growth factor (VEGF) and delta-like ligand 4 (DLL4). Combined VEGF and DLL4 blockade increased inhibition of subcutaneous xenograft growth of human colon cancer-derived cell lines versus blockade of either axis alone. In vivo, ABT-165 plus chemotherapy (CT) induced tumor regression with improved efficacy, vs anti-VEGF monoclonal antibody plus CT. In a phase 1 study, tolerable recommended phase 2 dose was identified for ABT-165 plus FOLFIRI and showed promising efficacy. This phase 2 trial in progress assesses efficacy/safety of ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients with second-line mCRC. Methods: This is an open-label, multicenter, phase 2 randomized (1:1) trial (NCT03368859) in patients (≥ 18 years; Eastern Cooperative performance status: 0–1) with histologically/cytologically confirmed mCRC who progressed after fluoropyrimidine/oxaliplatin and bev. ABT-165 (2.5 mg/kg) plus FOLFIRI (irinotecan: 180 mg/m<jats:sup>2</jats:sup>; leucovorin: 400 mg/m<jats:sup>2</jats:sup>; fluorouracil bolus: 400 mg/m<jats:sup>2</jats:sup>, infusion: 2400 mg/m<jats:sup>2</jats:sup>) or bev (5 mg/kg) plus FOLFIRI are given intravenously on day 1 of each 14-day cycle, until disease progression/intolerable toxicity. Primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), and safety. Exploratory endpoints include biomarkers predictive for efficacy/safety, correlation of DLL4 levels with PFS, OS, and ORR, pharmacodynamic effects, and efficacy/safety-exposure relationships in ABT-165 arm. Hazard ratios of PFS and OS comparing the 2 groups are estimated using Cox proportional hazard model. Kaplan-Meier methodology is used to estimate PFS and OS curves, median PFS and OS, and their 90% confidence intervals. Safety is assessed by ABT-165 exposure, adverse events (AEs), serious AEs, all deaths, and changes in laboratory data and vital signs. Archival tissue is collected and evaluated for DLL4 expression and angiogenesis signature. Approximately 100 patients are planned to be enrolled, with recruitment initiated January 2018. Clinical trial information: NCT03368859. </jats:p>
Authors
Wainberg, ZA; Wang, L; Yue, H; Motwani, M; Kasichayanula, S; Blaney, ME; Naumovski, L; Strickler, JH
MLA Citation
Wainberg, Zev A., et al. “ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab..” Journal of Clinical Oncology, vol. 37, no. 4_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. TPS720–TPS720. Crossref, doi:10.1200/jco.2019.37.4_suppl.tps720.
URI
https://scholars.duke.edu/individual/pub1416460
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
TPS720
End Page
TPS720
DOI
10.1200/jco.2019.37.4_suppl.tps720

Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

Authors
Strickler, JH; Zemla, T; Ou, F-S; Cercek, A; Wu, C; Sanchez, FA; Hubbard, J; Jaszewski, B; Bandel, L; Schweitzer, B; Niedzwiecki, D; Kemeny, N; Boland, PM; Ng, K; Bekaii-Saab, T
MLA Citation
URI
https://scholars.duke.edu/individual/pub1417835
Source
wos
Published In
Annals of Oncology
Volume
30
Published Date

Quantifying the evolution of tumor architecture using serial circulating tumor DNA.

<jats:p> 600 </jats:p><jats:p> Background: There is limited data regarding changes in the genomic landscape in individual patients over time as serial tissue biopsy has risk and is of uncertain clinical benefit. The advent of circulating tumor DNA (ctDNA) allows for safe and repeated molecular sampling with the potential to investigate evolution of tumor architecture over the disease course. Methods: From 5/15 to 12/17, 116 patients with metastatic CRC had between three to 12 blood specimens taken over the treatment course. Plasma was tested using targeted NGS assay (Guardant360, Guardant Health, 68 gene). To account for variations in the amount of ctDNA in serial samples, a window of evaluable allele frequency was established for each patient as the fold change between the max allele frequency (mAF) and limit of detection for serial samples with the lowest mAF. Mutations not falling within this window were excluded from analysis. Substantial treatment induced selective pressure (SP) was defined as a decrease in the mutant mAF of &gt; 50% in patients with at least an initial mAF of 1%. Results: 116 patients with a total of 317 serial blood samples were evaluable after accounting for ctDNA variations over time. Specimens were collected a median of 12 months apart, with a median of three specimens per patient. Thirteen patients (11%) did not have any changes in mutations on serial sampling, however the remainder of patients gained an average of 1.1 mutations per time point (mut/tp), and lost 1.0 mut/tp. 31% of patients demonstrated evidence of substantial treatment-induced SP. These patients were more likely to demonstrate a change in clonal architecture of the tumor (46% greater rate than those without SP, P = 0.04), predominantly through gain of new clones. In contrast, clonal hematopoiesis alterations that may be induced by chemotherapy, such as JAK2<jats:sup>V617F</jats:sup>, were neither gained or lost. Conclusions: After correction for variations over time in the total amount of ctDNA in circulation, we identify numerous changes in tumor architecture with serial sampling. For the first time in colorectal cancer we demonstrate that when treatment-induced SP is applied the rate of tumor evolution is increased, demonstrating potential value of monitoring changes in tumor architecture over the disease course. </jats:p>
Authors
Henry, J; Loree, JM; Strickler, JH; Raghav, KPS; Morris, VK; Raymond, VM; Lanman, RB; Yaeger, R; Corcoran, RB; Overman, MJ; Kopetz, S
MLA Citation
Henry, Jason, et al. “Quantifying the evolution of tumor architecture using serial circulating tumor DNA..” Journal of Clinical Oncology, vol. 37, no. 4_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 600–600. Crossref, doi:10.1200/jco.2019.37.4_suppl.600.
URI
https://scholars.duke.edu/individual/pub1416461
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
600
End Page
600
DOI
10.1200/jco.2019.37.4_suppl.600

Cell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States

Authors
Saori, M; Kawazoe, A; Nakamura, Y; Odegaard, JI; Lefterova, MI; Lanman, R; Yoshino, T; Strickler, JH
MLA Citation
URI
https://scholars.duke.edu/individual/pub1417836
Source
wos
Published In
Annals of Oncology
Volume
30
Published Date
Start Page
32
End Page
32